TScan Therapeutics Inc. (TCRX)
2.19
0.11 (5.29%)
At close: Feb 20, 2025, 3:59 PM
2.19
0.00%
After-hours: Feb 20, 2025, 05:18 PM EST
undefined% (undefined)
| Bid | 2.17 |
| Market Cap | 116.88M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.95 |
| PE Ratio (ttm) | -2.31 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.24 |
| Volume | 2,889,914 |
| Avg. Volume (20D) | 415,001 |
| Open | 2.11 |
| Previous Close | 2.08 |
| Day's Range | 2.04 - 2.21 |
| 52-Week Range | 1.99 - 9.69 |
| Beta | undefined |
About TCRX
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors....
Industry Biotechnology
Sector Healthcare
IPO Date Jul 16, 2021
Employees 188
Stock Exchange NASDAQ
Ticker Symbol TCRX
Website https://www.tscan.com
Analyst Forecast
According to 5 analyst ratings, the average rating for TCRX stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 402.28% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
TScan Therapeutics Inc. is scheduled to release its earnings on Mar 5, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
10 months ago
-7.28%
TScan Therapeutics shares are trading lower after ...
Unlock content with
Pro Subscription
